The Cooperative Research Centre for Cell Therapy Manufacturing (CTM CRC) has formed a strategic alliance with two international regenerative medicine translation centres, the Centre for Commercialization of Regenerative Medicine (CCRM) in Canada and the Cell Therapy Catapult in the UK. The alliance will provide CTM CRC, CCRM and the Cell Therapy Catapult a pathway for collaboration to further drive the development and commercialisation of cell therapies on a global level.
Cell therapies are being hailed as the next pillar of medicine due to their potential to use living cells to treat and possibly cure previously incurable diseases. CTM CRC, CCRM and the Cell Therapy Catapult are committed to bringing cell therapies to market that will enable the delivery of these life saving benefits to patients. Collaboration between the centres will open the door to new international networks, ideas and technical expertise that will fast-track this vision.
Keith Thompson, CEO of the Cell Therapy Catapult, said: “A high degree of collaboration among leading translational centres can help to advance commercial opportunities. The agreement we have made with CTM CRC will allow us to leverage international research and company networks to deliver health and wealth and fast-track the development of cell therapies for the global market.”
Agreements detailing the terms of this strategic alliance define opportunities for collaboration on potential joint projects and commercial opportunities, including research and development, commercialisation, clinical trials, standardisation and regulatory efforts, funding, reimbursement strategies, training programs, and other initiatives of mutual interest and benefit.
Michael May, President and CEO of the Centre for Commercialization of Regenerative Medicine, welcomed the collaboration saying: “The objectives of each of the centres are very tightly aligned; it makes sense that we would combine our strengths and resources. If we can push the commercialisation of promising technologies, not only will it create patient benefits, but there will be economic benefits as well.”
Cell therapy is one of the most anticipated advances of the century, with the global market estimated to grow to US$6.1 billion by 2020. The current level of activity and investment is also at a record high. Many of the world’s largest biomedical and pharmaceutical companies are investing heavily in research and development in cell therapies, including Novartis, Johnson and Johnson, Pfizer, Amgen and GSK. The strategic alliance between CTM CRC, CCRM and the Cell Therapy Catapult will augment each organisation’s efforts to capitalise on the opportunities and impact of cell therapies in their respective countries.
“By leveraging our combined international networks and expertise, we are ensuring that our endeavours in this promising field are as efficient and effective as possible, bringing cell therapies to market faster. Successful commercialisation of cell therapies will not only benefit patients, but promote the growth of a new, high value-add industry, creating jobs and opportunities for investment,” explained Dr Sherry Kothari, CEO, CTM CRC.
Click here for media release